A Phase II Open Label, Follow up Study to Investigate the Long Term Tolerability and Safety of Oral BIBF 1120 on Top of Pirfenidone in Japanese Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
Price : $35 *
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 01 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 03 Sep 2014 Planned End Date changed from 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 03 Sep 2014 Planned primary completion date changed from 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.